Selskabets formål er at markedsføre, promovere, importere, sælge og distribuere farmaceutiske og medicinske produkter, repræsentation af selskaber, supporterende services og forretningsassistance til interessenter i Europa, rådgivning og services i forbindelse med registrering af farmaceutiske produkter, forskning og udvikling af farmaceutiske produkter, kliniske forsøg, samt anden hertil knyttet virksomhed der ikke er forbudt ved lov. Selskabets formål er tillige at understøtte Novo Nordisk A/S farmaceutiske aktivitet. Selskabet tilstræber at drive sin virksomhed på økonomisk, miljømæssigt og socialt ansvarlig vis.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 2.4 mia. | 86.1 mio. | 1.1 mia. | 101.8 mio. | 294 | |
CVR: 38180045
Secondary names: Novo Nordisk Region Europe Pharmaceuticals A/S, Novo Nordisk North West Europe Pharmaceuticals A/S
Previous names: Novo Nordisk Region Europe Pharmaceuticals A/S
Compared to 406 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Jeppe Theisen joined the board
David Marcus Svensson joined the board
Malin Eva Maria Andreasen left the board
Anders Rytter Mikkelsen left the board
Companies in the same industry and area
CVR 41722460
CVR 39371049
CVR 39503778
CVR 40873309
CVR 31774284
Novo Nordisk Denmark A/S demonstrates a strong financial trajectory with significant revenue growth, increasing from 509.9 million DKK in 2022 to 2.37 billion DKK in 2024, reflecting a robust annual growth rate. Profitability has also improved, with profits rising from 33.5 million DKK in 2022 to 86.1 million DKK in 2024, indicating effective cost management and operational efficiency. The company's equity position has strengthened, growing from 49.1 million DKK in 2022 to 101.8 million DKK in 2024, which enhances its financial stability. Overall, Novo Nordisk is well-positioned within the pharmaceutical wholesale industry, showcasing resilience and a positive outlook for continued growth.
AI-generated summary
companydata.dk